Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Antibody Response to Pneumococcal Polysaccharide Vaccine in Systemic Sclerosis

ULISES MERCADO, HECTOR ACOSTA and RAUL DIAZ-MOLINA
The Journal of Rheumatology July 2009, 36 (7) 1549-1550; DOI: https://doi.org/10.3899/jrheum.081227
ULISES MERCADO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ulisesmercado@uabc.mx
HECTOR ACOSTA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RAUL DIAZ-MOLINA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Systemic sclerosis (SSc) is a connective tissue disorder characterized by cutaneous and visceral fibrosis, and obliterative vasculopathy. The lungs are frequently affected in SSc, and pulmonary disease may significantly influence morbidity and mortality1. Patients with SSc are at increased risk for microbial infections due to the immune effects of the disease itself, and the frequent use of immunosuppressive agents. Current guidelines recommend vaccination with pneumococcal polysaccharide for persons 2 to 64 years of age with chronic illness and for persons 65 years of age or older2,3. Therefore, vaccination might be useful in this infection-prone population provided that the vaccines produce a significant increase in antibody levels. To date, antibody responses to pneumococcal polysaccharide vaccine in patients with SSc are unknown. We evaluated the immunogenicity of this commercial vaccine in patients with SSc during promotional campaigns.

Eighteen consecutive patients with SSc, according to the American College of Rheumatology criteria4, attending our outpatient clinic were included. Patients were grouped in subsets as defined by LeRoy, et al5. Patients who had received pneumococcus vaccination within 5 years prior to study were excluded. There were 17 women and one man of median age 46.5 years (range 31–62) and median disease duration 7.5 years (range 1–12). Diffuse cutaneous SSc (dcSSc) was present in 12 patients and limited cutaneous SSc (lcSSc) in 6. Antibody against DNA topoisomerase I was positive in 10 patients and 3 patients had anticentromere antibody. The mean modified Rodnan skin score was 16.7 (range 8–32). At the time of vaccination, 2 SSc patients had received intravenous cyclophosphamide, 5 were receiving low-dose prednisone (2.5–5.0 mg/day), 5 colchicine, and one D-penicillamine. Metoclopramide, proton-pump inhibitors, and vasodilators were a part of their drug therapy.

Each patient received an intradeltoid injection with 0.5 ml pneumococcal vaccine (23-valent Pulmovax; Merck Sharp & Dohme). Antibody concentrations to 4 antigens (4, 6B, 12F, and 14; American Type Culture Collection, Manassas, VA, USA) were measured by enzyme-immunoassay. These serotypes represent those most frequently encountered in our region. Serum samples were collected prior to and 4 weeks after vaccination administration.

Capsular antigens were bound to 96-well polystyrene microtiter plates at 0.5 μg per 100 μl phosphate-buffered saline (PBS) per well by overnight incubation at 4°C. Sera were applied to plates at initial dilution of 1:100 in 1% bovine serum albumin with 0.05% Tween 20 in PBS. Bound antibodies were detected with a conjugated probe, followed by substrate addition. The levels of each specific antibody were calculated relative to the amount of color development. A ≥ 2-fold rise in antibody titer was considerated as a protective response.

Differences in antibody titers before and after vaccination were calculated by Wilcoxon signed-rank test. Differences in median antibody levels between patients with lcSSc and dcSSc were investigated by Mann-Whitney U-test. A p value < 0.05 was considerated significant. The fold-rise in serotype-specific IgG was calculated for each subject as the postvaccination titer divided by the prevaccination titer. The percentage of patients with ≥ 2-fold increases in antibody levels was analyzed.

Mean antibody levels to the 4 different pneumococcal capsular polysaccharides before and 4 weeks after vaccination are shown in Table 1. Prior to vaccination, mean antibody levels ranged from 48 to 70 ng/ml. One month after vaccination, mean levels increased significantly to the 4 capsular antigens (range 127 to 169 ng/ml; p < 0.05). On average, antibody titers rose from 2.3 (for capsular antigen 12F) to 3.3 (for capsular antigen 6B). A ≥ 2-fold rise in antibody titer to at least one capsular antigen was achieved by 100% of patients, and 83% achieved a ≥ 2-fold rise to ≥ 3 of 4 capsular antigens.

View this table:
  • View inline
  • View popup
Table 1.

Antibody levels before and after pneumococcal vaccination (nanograms IgG per ml) and number (%) of patients with ≥ 2-fold rise in antibody levels.

Among the cyclophosphamide-treated patients, one achieved a ≥ 2-fold rise to serotypes 4, 6, and 14 (2.9, 4.0, and 2.0, respectively), whereas in the other patient, serotypes 4 and 14 were the most immunogenic (3.4 and 2.0, respectively). No significant difference in the median pneumococcal antibody titers pre- and postvaccination was observed between patients with lcSSc and those with dcSSc (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Median antibody levels before and after pneumococcal vaccination (nanograms IgG per ml) between lcSSc (n = 6) and dcSSc (n = 12) patients.

We also investigated the persistence of protective pneumococcal antibodies in 10 subjects one year after administration of pneumococcal polysaccharide vaccine; all showed mean decreased antibody levels, compared with mean postvaccination antibody levels (Table 1). None had pneumonia or renal crisis. Two patients had pain at the injection site.

We observed that the patients with SSc developed a protective antibody response to the 4 capsular antigens tested. A ≥ 2-fold rise in titer to one serotype was achieved by 100% of the patients, and to 3 or more serotypes by 83% of patients, including patients taking immunosuppressive drugs. The followup of 10 out of 18 patients with SSc at 1 year, however, revealed mean antibody levels lower than postvaccination levels. Previously, the author critically reviewed the literature on vaccination in rheumatic diseases and evaluated the effect of pneumococcal vaccine in patients with systemic lupus erythematosus (SLE). In that study, 3 out of 4 capsular antigens were also tested (12F, 6B, and 14). One month after vaccine administration, 9 of 12 patients achieved a ≥ 2-fold rise in titer of protective antibodies6,7.

Other investigators8,9 have reported that pneumococcal vaccinations in patients with SLE and other chronic rheumatic diseases were safe and immunogenic, albeit lower than in controls. We did not investigate whether pneumococcal vaccine in SSc patients triggers the generation of disease-specific autoantibodies and/or clinical exacerbation of SSc. To date, there is no evidence of a pathogenic relationship between systemic autoimmunity and the clinical features of SSc10. According to Hudson, et al11, who critically reviewed the literature on global measures of disease activity in SSc, there is currently no gold standard measure of disease activity in SSc.

Our study had the following limitations: small number of patients, the lack of a control group, and the absence of safety assessment. However, we showed (1) that both lcSSc and dcSSc patients generated protective antibody levels in similar form to the 4 antigens tested at 1 month after vaccination; (2) that 83% of the patients achieved protective antibody levels to 3 or more capsular antigens; and (3) that the antibody response was independent of treatment with immunosuppressive drugs.

REFERENCES

  1. 1.↵
    1. Silver RM,
    2. Miller KS
    . Lung involvement in systemic sclerosis. Rheum Dis Clin N Am 1990;16:199–216.
    OpenUrlPubMed
  2. 2.↵
    1. Centers for Disease Control and Prevention
    . Prevention of pneumococcal disease: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1977;45:1–24.
    OpenUrl
  3. 3.↵
    1. Whitney CG
    . Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age ≥ 65. Geriatrics 2003;58:20–2; 25.
    OpenUrl
  4. 4.↵
    1. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee
    . Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581–90.
    OpenUrlPubMed
  5. 5.↵
    1. LeRoy EC,
    2. Krieg T,
    3. Black CM,
    4. et al
    . Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202–5.
    OpenUrlPubMed
  6. 6.↵
    1. Mercado U
    . Antibody responses following vaccination in lupus patients. Rev Invest Clin 2003;55:93–4.
    OpenUrlPubMed
  7. 7.↵
    1. Mercado U
    . Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus [editorial]. J Rheumatol 2006;33:1469–71.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Elkayam O,
    2. Paran D,
    3. Burke M,
    4. et al
    . Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies. Autoimmunity 2005;38:493–6.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Mease PJ,
    2. Ritchlin CT,
    3. Martin RW,
    4. et al
    . Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356–61.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Arnett FC
    . Is scleroderma an autoantibody mediated disease? Curr Opin Rheumatol 2006;18:579–81.
    OpenUrlPubMed
  11. 11.↵
    1. Hudson M,
    2. Steele R,
    3. Canadian Scleroderma Research Group (CSRG),
    4. Baron M
    . Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007;37:93–8.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 36, Issue 7
1 Jul 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antibody Response to Pneumococcal Polysaccharide Vaccine in Systemic Sclerosis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antibody Response to Pneumococcal Polysaccharide Vaccine in Systemic Sclerosis
ULISES MERCADO, HECTOR ACOSTA, RAUL DIAZ-MOLINA
The Journal of Rheumatology Jul 2009, 36 (7) 1549-1550; DOI: 10.3899/jrheum.081227

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Antibody Response to Pneumococcal Polysaccharide Vaccine in Systemic Sclerosis
ULISES MERCADO, HECTOR ACOSTA, RAUL DIAZ-MOLINA
The Journal of Rheumatology Jul 2009, 36 (7) 1549-1550; DOI: 10.3899/jrheum.081227
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Does the BNT162b2 Vaccine Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody–Positive Interstitial Lung Disease?
  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire